دورية أكاديمية
Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab.
| العنوان: | Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. |
|---|---|
| المؤلفون: | Kiss C; Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria., Michels S, Prager F, Weigert G, Geitzenauer W, Schmidt-Erfurth U |
| المصدر: | Retina (Philadelphia, Pa.) [Retina] 2006 Oct; Vol. 26 (8), pp. 877-81. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8309919 Publication Model: Print Cited Medium: Print ISSN: 0275-004X (Print) Linking ISSN: 0275004X NLM ISO Abbreviation: Retina Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: Philadelphia : Lippincott, [1981?- |
| مواضيع طبية MeSH: | Angiogenesis Inhibitors/*therapeutic use , Anterior Chamber/*immunology , Antibodies, Monoclonal/*therapeutic use , Choroidal Neovascularization/*drug therapy , Inflammation/*diagnosis , Macular Degeneration/*drug therapy , Vascular Endothelial Growth Factor A/*immunology, Anterior Chamber/pathology ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Cell Count ; Choroidal Neovascularization/etiology ; Diagnostic Techniques, Ophthalmological ; Humans ; Injections ; Macular Degeneration/complications ; Microscopy ; Uveitis, Anterior/diagnosis |
| مستخلص: | Purpose: To evaluate the effect of intravitreal bevacizumab on anterior chamber inflammatory activity. Methods: Sixty-one consecutive patients with neovascular age-related macular degeneration were examined before, 1 day, and 1 week after intravitreal administration of 1 mg of bevacizumab (0.04 mL) for neovascular age-related macular degeneration. The intravitreal injection was performed under sterile conditions. Twenty-one fellow eyes served as controls. The anterior chamber inflammatory activity was evaluated using biomicroscopy and the laser flare meter (Kowa FM-500, Kowa Company, Ltd., Tokyo, Japan). Results: None of the 61 consecutive patients had a significant, clinically detectable inflammatory response within 1 week of follow-up. Anterior chamber inflammatory activity measured by the laser flare meter ranged from 1.9 counts/ms to 70.0 counts/ms (mean +/- SD, 13.2 +/- 16.9 counts/ms; 95% confidence interval [CI], 7.8-18.6) before treatment. One day and 1 week after injection, values were between 3.2 counts/ms and 30.0 counts/ms (mean +/- SD, 9.1 +/- 6.2 counts/ms; 95% CI, 7.2-11.1) and 2.0 counts/ms and 25.1 counts/ms (mean +/- SD, 7.3 +/- 4.6 counts/ms; 95% CI, 5.8-8.8), respectively. There was a significant reduction of anterior chamber flare at 1 week compared with baseline (P = 0.031). The control eyes had constantly low flare measures. Conclusion: No inflammatory response was detected clinically and by the laser flare meter after intravitreal bevacizumab administration. The slight reduction in anterior chamber flare could be due to the known antiinflammatory effect of anti-vascular endothelial growth factor therapy. |
| المشرفين على المادة: | 0 (Angiogenesis Inhibitors) 0 (Antibodies, Monoclonal) 0 (Antibodies, Monoclonal, Humanized) 0 (VEGFA protein, human) 0 (Vascular Endothelial Growth Factor A) 2S9ZZM9Q9V (Bevacizumab) |
| تواريخ الأحداث: | Date Created: 20061013 Date Completed: 20061107 Latest Revision: 20151119 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1097/01.iae.0000237080.10627.b7 |
| PMID: | 17031286 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0275-004X |
|---|---|
| DOI: | 10.1097/01.iae.0000237080.10627.b7 |